MedTrace Logo

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

NCT03540160 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 558

Last updated 2021-05-20

Study results available
· View outcomes & findings →

Summary

Study of the long term safety of serlopitant for the treatment of pruritus in adults.

Conditions

Interventions

DRUG

5 mg Serlopitant Tablets

Serlopitant Tablets

Sponsors & Collaborators

  • Vyne Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-15
Primary Completion
2020-04-08
Completion
2020-06-17
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03540160 on ClinicalTrials.gov